About Wyeth

Wyeth is a research-based, global pharmaceutical company responsible for the discovery and development of some of today's most innovative medicines. Our products are sold in more than 140 countries, and our product portfolio includes innovative treatments across a wide range of therapeutic areas. Our worldwide resources include more than 52,000 employees, manufacturing facilities on five continents, and a discovery and development platform encompassing pharmaceuticals, vaccines and biotechnology.
Our employees are united in a common mission with shared values that will allow us to achieve an ambitious vision: to be recognized as the best pharmaceutical company in the world..
The Company has a unique combination of strategic assets that set us apart from our competitors:

  • Strong foundation products - Our current product portfolio includes the Premarin® (conjugated estrogens tablets, USP) family of products - which became Wyeth's first $2 billion product line in 2001 (Please see Important Warning and Perscribing Information) - and Effexor® (venlafaxine HCl) Tablets / Effexor® XR (venlafaxine HCl) Extended-Release Capsules, which reached $1.5 billion in sales in 2001. We also have some of the world's best-known customer health care brands, including, Advil, Centrum and Robitussin.
  • Successful new products- In the last three years, Wyeth has launched nine new products and, since 1998, initiated three of the 10 most successful prescription medication launches of all time: Enbrel® (etanercept), Prevnar®, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein) and Protonix® (pantoprazole sodium). These three products together produced sales of more than $2.2 billion in 2001 and all have the potential to exceed $1 billion in annual sales in the near future. Two important new products - an innovative intranasal flu vaccine and a locally applied recombinant bone growth factor are currently under health authority review.
  • Favorable patent situation- With the success of our new products, Wyeth has one of the lowest exposures to patent expiration of all the major pharmaceutical companies over the next seven to eight years - a tremendous competitive advantage. Our broad-based portfolio also means that our growth is not dependent on the success or patent life of one or two products.
  • Robust pipeline- We have built an impressive new product pipeline across a wide range of therapeutic areas that addresses significant unmet medical needs. By 2004-2005, we expect this pipeline to yield several new first-or best-in-class products.
  • Unique R&D technology base- Wyeth now is one of the largest biotechnology companies in the world and one of a select few major pharmaceutical companies with significant research programs, manufacturing capabilities and marketed products from three discovery and development platforms: pharmaceuticals, vaccines and biotechnology. This breadth of expertise provides unique research synergies and fuels our ability to explore multiple paths in the search for new therapies.
  • Our People - All of these assets are driven by our most important resource: the talent, commitment and experience of our dedicated employees around the world.
    •  

    AHP Is Now Wyeth
    Our new name reflects our evolution from a holding company with diversified businesses to a global leader in research-based pharmaceuticals that address the world's most serious health problems. Learn more. =>

    Our Mission
    We bring to the world pharmaceutical and health care products that improve lives and deliver outstanding value to our customers and shareholders.

    Our Vision
    Our vision is to lead the way to a healthier world. By carrying out this vision at every level of our organization, we will be recognized by our employees, customers and shareholders as the best pharmaceutical company in the world, resulting in value for all.

    We will achieve this by:

  • Leading the world in innovation by linking pharmaceutical, biotech and vaccines technologies
  • Making quality, integrity and excellence hallmarks of the way we do business >
  • Attracting, developing and motivating the best people
  • Continually growing and improving our business

    • Our Values
    Quality
    Integrity
    Respect for People
    Leadership
    Collaboration

    Quality
    We are committed to excellence - in the results we achieve and in how we achieve them
  • Do our jobs right every time
  • Focus on what's important
  • Strive for continuous improvement
  • Think strategically and execute flawlessly

    Integrity
    We do what is right for our customers, our communities, our shareholders and ourselves
  • Take responsibility for our actions
  • Follow through on commitments
  • Communicate in an open, honest and authentic manner
  • Respect confidentiality

    Respect for People
    We promote a diverse culture and an environment of mutual respect for our employees, our customers and our communities
  • Treat others with dignity and respect
  • Embrace and encourage new ideas
  • Cultivate individual talents
  • Reward contributions
  • Celebrate achievements

    Leadership
    We value people at every level who lead by example, take pride in what they do and inspire others
  • Be role models
  • Approach our jobs with passion and conviction
  • Bring out the best in people
  • Anticipate change
  • Demonstrate personal initiative
  • Promote innovative thinking

    Collaboration
    We value teamwork - working together to achieve common goals is the foundation of our success
  • Be flexible and responsive
  • Think and work across boundaries
  • Share information freely
  • Seek input and listen
    The Company's success is the goal of each of us and is the outcome of operating according to our values.
    		•